U.K. Venture Group Abingworth Attracts $375M For New Bioventures Fund
This article was originally published in The Pink Sheet Daily
The BioVentures VI fund will invest across the life sciences sector in Europe and the U.S. and could herald an uptick in VC fundraising activity.
You may also be interested in...
The Paris-based start-up has raised €32 million from venture investors to address two orphan eye disorders, taking advantage of new research and manufacturing techniques in gene therapy.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.